Comparison of HIV incidence estimated in clinical trial and observational cohort settings in a high risk fishing population in Uganda: Implications for sample size estimates
Abstract Background Clinical trial participants may differ from the source population due to the demands of trial participation and self-selection, inadvertent selection of a lower-risk group, or both. We investigated the HIV risk status of volunteers in a Simulated Vaccine Efficacy Trial (SiVET) ne...
Saved in:
Published in | Vaccine Vol. 34; no. 15; pp. 1778 - 1785 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier Ltd
04.04.2016
Elsevier Limited |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract Background Clinical trial participants may differ from the source population due to the demands of trial participation and self-selection, inadvertent selection of a lower-risk group, or both. We investigated the HIV risk status of volunteers in a Simulated Vaccine Efficacy Trial (SiVET) nested within a prospective observational cohort of fisher folks in South Western Uganda. Methods Volunteers aged 18–49 years, at high risk for HIV from fishing communities in Masaka district were recruited into an observational cohort and followed quarterly. High risk was defined as a self-report, of at least one of the following in the past three months; sexually transmitted infections, unprotected sex with >1 partner or a new sexual partner, use of recreational drugs, weekly alcohol use, and/or frequent travel. Volunteers who had at least three months of follow-up in the observational cohort were consecutively enrolled in SiVET, administered Hepatitis B vaccine at months (0, 1, 6) and followed-up three days post vaccinations to mimic a vaccine trial schedule. HIV incidence over the next 12 months was compared between SiVET and the observational cohort studies. Results Between January 2012 and February 2013, 575 individuals were enrolled in the observational cohort, of whom 282 were enrolled in SiVET between July 2012 and February 2013. Despite similar pattern of reported risk behaviour in both studies, HIV incidence was higher in observational cohort, 11.4 cases/100 PYO [95% CI: 7.4–17.7] compared to 3.8 [95% CI: 2.0–7.0] in SiVET ( p < 0.01). SiVET volunteers tended to be men, having some education and longer-term residents, all factors that are also associated with lower HIV risk. Conclusion We observed a lower HIV incidence in SiVET than in the observational cohort. The two populations differed significantly in demographics but not in reported risk. HIV incidence estimates from observational cohorts must be used with caution to estimate the trial study size. |
---|---|
AbstractList | Background Clinical trial participants may differ from the source population due to the demands of trial participation and self-selection, inadvertent selection of a lower-risk group, or both. We investigated the HIV risk status of volunteers in a Simulated Vaccine Efficacy Trial (SiVET) nested within a prospective observational cohort of fisher folks in South Western Uganda. Methods Volunteers aged 18-49 years, at high risk for HIV from fishing communities in Masaka district were recruited into an observational cohort and followed quarterly. High risk was defined as a self-report, of at least one of the following in the past three months; sexually transmitted infections, unprotected sex with >1 partner or a new sexual partner, use of recreational drugs, weekly alcohol use, and/or frequent travel. Volunteers who had at least three months of follow-up in the observational cohort were consecutively enrolled in SiVET, administered Hepatitis B vaccine at months (0, 1, 6) and followed-up three days post vaccinations to mimic a vaccine trial schedule. HIV incidence over the next 12 months was compared between SiVET and the observational cohort studies. Results Between January 2012 and February 2013, 575 individuals were enrolled in the observational cohort, of whom 282 were enrolled in SiVET between July 2012 and February 2013. Despite similar pattern of reported risk behaviour in both studies, HIV incidence was higher in observational cohort, 11.4 cases/100 PYO [95% CI: 7.4-17.7] compared to 3.8 [95% CI: 2.0-7.0] in SiVET (p<0.01). SiVET volunteers tended to be men, having some education and longer-term residents, all factors that are also associated with lower HIV risk. Conclusion We observed a lower HIV incidence in SiVET than in the observational cohort. The two populations differed significantly in demographics but not in reported risk. HIV incidence estimates from observational cohorts must be used with caution to estimate the trial study size. BACKGROUNDClinical trial participants may differ from the source population due to the demands of trial participation and self-selection, inadvertent selection of a lower-risk group, or both. We investigated the HIV risk status of volunteers in a Simulated Vaccine Efficacy Trial (SiVET) nested within a prospective observational cohort of fisher folks in South Western Uganda.METHODSVolunteers aged 18-49 years, at high risk for HIV from fishing communities in Masaka district were recruited into an observational cohort and followed quarterly. High risk was defined as a self-report, of at least one of the following in the past three months; sexually transmitted infections, unprotected sex with >1 partner or a new sexual partner, use of recreational drugs, weekly alcohol use, and/or frequent travel. Volunteers who had at least three months of follow-up in the observational cohort were consecutively enrolled in SiVET, administered Hepatitis B vaccine at months (0, 1, 6) and followed-up three days post vaccinations to mimic a vaccine trial schedule. HIV incidence over the next 12 months was compared between SiVET and the observational cohort studies.RESULTSBetween January 2012 and February 2013, 575 individuals were enrolled in the observational cohort, of whom 282 were enrolled in SiVET between July 2012 and February 2013. Despite similar pattern of reported risk behaviour in both studies, HIV incidence was higher in observational cohort, 11.4 cases/100 PYO [95% CI: 7.4-17.7] compared to 3.8 [95% CI: 2.0-7.0] in SiVET (p<0.01). SiVET volunteers tended to be men, having some education and longer-term residents, all factors that are also associated with lower HIV risk.CONCLUSIONWe observed a lower HIV incidence in SiVET than in the observational cohort. The two populations differed significantly in demographics but not in reported risk. HIV incidence estimates from observational cohorts must be used with caution to estimate the trial study size. Clinical trial participants may differ from the source population due to the demands of trial participation and self-selection, inadvertent selection of a lower-risk group, or both. We investigated the HIV risk status of volunteers in a Simulated Vaccine Efficacy Trial (SiVET) nested within a prospective observational cohort of fisher folks in South Western Uganda. Volunteers aged 18–49 years, at high risk for HIV from fishing communities in Masaka district were recruited into an observational cohort and followed quarterly. High risk was defined as a self-report, of at least one of the following in the past three months; sexually transmitted infections, unprotected sex with >1 partner or a new sexual partner, use of recreational drugs, weekly alcohol use, and/or frequent travel. Volunteers who had at least three months of follow-up in the observational cohort were consecutively enrolled in SiVET, administered Hepatitis B vaccine at months (0, 1, 6) and followed-up three days post vaccinations to mimic a vaccine trial schedule. HIV incidence over the next 12 months was compared between SiVET and the observational cohort studies. Between January 2012 and February 2013, 575 individuals were enrolled in the observational cohort, of whom 282 were enrolled in SiVET between July 2012 and February 2013. Despite similar pattern of reported risk behaviour in both studies, HIV incidence was higher in observational cohort, 11.4 cases/100 PYO [95% CI: 7.4–17.7] compared to 3.8 [95% CI: 2.0–7.0] in SiVET (p<0.01). SiVET volunteers tended to be men, having some education and longer-term residents, all factors that are also associated with lower HIV risk. We observed a lower HIV incidence in SiVET than in the observational cohort. The two populations differed significantly in demographics but not in reported risk. HIV incidence estimates from observational cohorts must be used with caution to estimate the trial study size. Abstract Background Clinical trial participants may differ from the source population due to the demands of trial participation and self-selection, inadvertent selection of a lower-risk group, or both. We investigated the HIV risk status of volunteers in a Simulated Vaccine Efficacy Trial (SiVET) nested within a prospective observational cohort of fisher folks in South Western Uganda. Methods Volunteers aged 18–49 years, at high risk for HIV from fishing communities in Masaka district were recruited into an observational cohort and followed quarterly. High risk was defined as a self-report, of at least one of the following in the past three months; sexually transmitted infections, unprotected sex with >1 partner or a new sexual partner, use of recreational drugs, weekly alcohol use, and/or frequent travel. Volunteers who had at least three months of follow-up in the observational cohort were consecutively enrolled in SiVET, administered Hepatitis B vaccine at months (0, 1, 6) and followed-up three days post vaccinations to mimic a vaccine trial schedule. HIV incidence over the next 12 months was compared between SiVET and the observational cohort studies. Results Between January 2012 and February 2013, 575 individuals were enrolled in the observational cohort, of whom 282 were enrolled in SiVET between July 2012 and February 2013. Despite similar pattern of reported risk behaviour in both studies, HIV incidence was higher in observational cohort, 11.4 cases/100 PYO [95% CI: 7.4–17.7] compared to 3.8 [95% CI: 2.0–7.0] in SiVET ( p < 0.01). SiVET volunteers tended to be men, having some education and longer-term residents, all factors that are also associated with lower HIV risk. Conclusion We observed a lower HIV incidence in SiVET than in the observational cohort. The two populations differed significantly in demographics but not in reported risk. HIV incidence estimates from observational cohorts must be used with caution to estimate the trial study size. |
Author | Fast, Patricia E Asiki, Gershim Kamali, Anatoli Ruzagira, Eugene Kibengo, Freddie Price, Matthew A Bahemuka, Ubaldo Abaasa, Andrew |
AuthorAffiliation | b International AIDS Vaccine Initiative, New York, USA a MRC/UVRI, Uganda Research Unit on AIDS, Entebbe Uganda c University of California at San Francisco, Department of Epidemiology and Biostatistics, San Francisco, USA |
AuthorAffiliation_xml | – name: b International AIDS Vaccine Initiative, New York, USA – name: a MRC/UVRI, Uganda Research Unit on AIDS, Entebbe Uganda – name: c University of California at San Francisco, Department of Epidemiology and Biostatistics, San Francisco, USA |
Author_xml | – sequence: 1 fullname: Abaasa, Andrew – sequence: 2 fullname: Asiki, Gershim – sequence: 3 fullname: Price, Matthew A – sequence: 4 fullname: Ruzagira, Eugene – sequence: 5 fullname: Kibengo, Freddie – sequence: 6 fullname: Bahemuka, Ubaldo – sequence: 7 fullname: Fast, Patricia E – sequence: 8 fullname: Kamali, Anatoli |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26923456$$D View this record in MEDLINE/PubMed |
BookMark | eNqNUkFv0zAYtdAQ6wo_AWSJC5cW20kcm8MQqoBVmsQBhrhZjvOlcZfYwU4rjf_Ef8Sh3Qa7wMWWn997frbfGTpx3gFCzylZUkL56-1yr42xDpYsLZeELUkuHqEZFWW2YAUVJ2hGGM8XOSXfTtFZjFtCSJFR-QSdMi5Zlhd8hn6ufD_oYKN32Df4Yv0VW2dsDc4AhjjaXo9QJwybzjprdIfHYNOoXY19FSHs9Wi9S4jxrQ8jjjCO1m3ipNG4tZsWJ_tr3NjYJhwPfth1vzUT42qTjPQbvO6HLrlPcMSNDzjqhACO9sd9jvgUPW50F-HZcZ6jqw_vv6wuFpefPq5X7y4XphDZuCgARFPSsiKcZlpIAlI2VVHkvNYZMVXd5JVkpagrrinkdZMxmZdZxg2IkqXlHJ0ffIdd1UNtwI1Bd2oIKUa4UV5b9feOs63a-L3KpcyFkMng1dEg-O-7lF_1NhroOu3A76KiZck5FxkT_0MtKJeCTa4vH1C3fhfS2x8MaUFY-uE5Kg4sE3yMAZq73JSoqTtqq47dUVN3FGEqdSfpXvx56TvVbVkS4e2BAOnp9xaCisZORaltADOq2tt_HnH-wOG2VddwA_H-Niomgfo8FXjqL-WEMJZi_AJJCfL9 |
CitedBy_id | crossref_primary_10_1007_s10461_019_02483_y crossref_primary_10_1186_s12982_018_0079_5 crossref_primary_10_1186_s12889_022_14875_2 crossref_primary_10_1089_aid_2019_0228 crossref_primary_10_1007_s10508_021_02180_9 crossref_primary_10_1186_s12879_019_4328_1 crossref_primary_10_1186_s12874_020_00920_4 crossref_primary_10_1371_journal_pone_0198460 crossref_primary_10_1371_journal_pone_0214786 crossref_primary_10_1371_journal_pone_0290634 crossref_primary_10_1371_journal_pone_0185818 crossref_primary_10_1186_s12889_020_09932_7 crossref_primary_10_1038_s41598_021_86539_x crossref_primary_10_1016_j_vaccine_2019_02_072 crossref_primary_10_1186_s12889_020_09085_7 crossref_primary_10_1186_s12889_023_17339_3 crossref_primary_10_1371_journal_pone_0249465 crossref_primary_10_1016_S2214_109X_19_30410_3 crossref_primary_10_1007_s10461_020_02838_w crossref_primary_10_1038_s41598_019_51879_2 crossref_primary_10_1177_17455057221103993 crossref_primary_10_1016_S2214_109X_20_30108_X |
Cites_doi | 10.4236/wja.2014.42027 10.1016/S0140-6736(09)61118-1 10.1136/sti.2010.046805 10.1186/1471-2458-14-986 10.1371/journal.pone.0001312 10.1371/journal.pone.0001474 10.1207/S15324796ABM2602_03 10.1016/j.vaccine.2013.08.080 10.1001/jama.288.3.358 10.1016/S0140-6736(10)61086-0 10.1371/journal.pone.0070770 10.1186/1745-6215-10-99 10.1111/j.1365-3156.2008.02200.x 10.1056/NEJMoa1108524 10.1371/journal.pone.0116100 10.1097/OLQ.0b013e318251555d 10.1056/NEJMoa0707957 10.1097/OLQ.0b013e3182099545 10.1371/journal.pone.0020684 10.1186/s13104-015-1804-6 |
ContentType | Journal Article |
Copyright | The Authors 2016 The Authors Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved. Copyright Elsevier Limited Apr 4, 2016 |
Copyright_xml | – notice: The Authors – notice: 2016 The Authors – notice: Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved. – notice: Copyright Elsevier Limited Apr 4, 2016 |
DBID | 6I. AAFTH CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7QL 7RV 7T2 7T5 7U9 7X7 7XB 88C 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9- K9. KB0 LK8 M0R M0S M0T M1P M2O M7N M7P MBDVC NAPCQ PQEST PQQKQ PQUKI Q9U 7X8 7U2 5PM |
DOI | 10.1016/j.vaccine.2016.02.048 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) ProQuest Nursing & Allied Health Database Health and Safety Science Abstracts (Full archive) Immunology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Pharma Collection ProQuest Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts SciTech Premium Collection Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Biological Sciences Consumer Health Database Health & Medical Collection (Alumni Edition) ProQuest Health Management Database PML(ProQuest Medical Library) Research Library Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central Basic MEDLINE - Academic Safety Science and Risk PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Research Library Prep ProQuest Central Student ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) Environmental Sciences and Pollution Management ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Research Library Health & Safety Science Abstracts ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest Central Basic ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) Immunology Abstracts ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic Safety Science and Risk |
DatabaseTitleList | AIDS and Cancer Research Abstracts Research Library Prep MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Veterinary Medicine Biology Pharmacy, Therapeutics, & Pharmacology Public Health |
EISSN | 1873-2518 |
EndPage | 1785 |
ExternalDocumentID | 4000868771 10_1016_j_vaccine_2016_02_048 26923456 S0264410X16002292 1_s2_0_S0264410X16002292 |
Genre | Research Support, U.S. Gov't, Non-P.H.S Research Support, Non-U.S. Gov't Journal Article Observational Study Research Support, N.I.H., Extramural |
GeographicLocations | Uganda |
GeographicLocations_xml | – name: Uganda |
GrantInformation_xml | – fundername: NIMH NIH HHS grantid: R25 MH064712 |
GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 0SF 123 1B1 1P~ 1RT 1~. 1~5 29Q 3V. 4.4 457 4G. 53G 5RE 5VS 7-5 71M 7RV 7X7 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8G5 8P~ 9JM AAAJQ AABNK AACTN AAEDT AAEDW AAHBH AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AARKO AAXKI AAXUO ABBQC ABFNM ABFRF ABJNI ABKYH ABMAC ABMZM ABRWV ABUWG ABXDB ACDAQ ACGFO ACGFS ACIUM ACPRK ACRLP ADBBV ADEZE ADFRT ADMUD ADVLN AEBSH AEFWE AEKER AENEX AEVXI AEXOQ AFCTW AFJKZ AFKRA AFKWA AFRAH AFRHN AFTJW AFXIZ AGEKW AGGSO AGHFR AGUBO AGYEJ AHHHB AHMBA AIEXJ AIKHN AITUG AJOXV AJRQY AJUYK AKRWK ALIPV ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX AQUVI ASPBG AVWKF AXJTR AZFZN AZQEC BBNVY BENPR BHPHI BKEYQ BKNYI BKOJK BLXMC BNPGV BPHCQ BVXVI CCPQU CJTIS CNWQP CS3 DWQXO EBS EFJIC EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-2 G-Q GBLVA GNUQQ GUQSH HCIFZ HEJ HLV HMG HMK HMO HVGLF HX~ HZ~ IHE J1W K9- KOM L7B LK8 LUGTX LW9 M0R M0T M1P M29 M2O M41 M7P MO0 N9A NAPCQ O-L O9- O9~ OAUVE OK0 OZT P-8 P-9 P2P PC. PQQKQ PROAC PSQYO Q38 R2- RIG ROL RPZ SAB SAE SCC SDF SDG SDP SES SEW SIN SNL SPCBC SSH SSI SSZ SVS T5K UV1 WH7 WOW WUQ XPP Z5R ZGI ZXP ~G- 6I. AAFTH AAIAV ABLVK ABYKQ AESVU AJBFU EFLBG HMCUK LCYCR QYZTP UKHRP CGR CUY CVF ECM EIF NPM AAYXX ACRPL CITATION 7QL 7T2 7T5 7U9 7XB 8FK C1K H94 K9. M7N MBDVC PQEST PQUKI Q9U 7X8 7U2 5PM |
ID | FETCH-LOGICAL-c583t-5ee8f717b0613a890e99fb5546da30cbdf4b9278db6a1e4df32947336ce872df3 |
IEDL.DBID | AIKHN |
ISSN | 0264-410X |
IngestDate | Tue Sep 17 21:10:22 EDT 2024 Wed Dec 04 01:19:26 EST 2024 Wed Dec 04 04:23:01 EST 2024 Fri Nov 08 08:08:03 EST 2024 Fri Dec 06 01:48:21 EST 2024 Sat Sep 28 07:58:11 EDT 2024 Fri Feb 23 02:21:12 EST 2024 Tue Oct 15 22:55:56 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 15 |
Keywords | Estimate HIV Sample Size Vaccines Incidence Implications |
Language | English |
License | http://creativecommons.org/licenses/by-nc-nd/4.0 Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c583t-5ee8f717b0613a890e99fb5546da30cbdf4b9278db6a1e4df32947336ce872df3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Undefined-2 ObjectType-Feature-2 |
ORCID | 0000-0002-9512-1571 |
OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0264410X16002292 |
PMID | 26923456 |
PQID | 1776150205 |
PQPubID | 105530 |
PageCount | 8 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4994889 proquest_miscellaneous_1776668328 proquest_miscellaneous_1775169829 proquest_journals_1776150205 crossref_primary_10_1016_j_vaccine_2016_02_048 pubmed_primary_26923456 elsevier_sciencedirect_doi_10_1016_j_vaccine_2016_02_048 elsevier_clinicalkeyesjournals_1_s2_0_S0264410X16002292 |
PublicationCentury | 2000 |
PublicationDate | 2016-04-04 |
PublicationDateYYYYMMDD | 2016-04-04 |
PublicationDate_xml | – month: 04 year: 2016 text: 2016-04-04 day: 04 |
PublicationDecade | 2010 |
PublicationPlace | Netherlands |
PublicationPlace_xml | – name: Netherlands – name: Kidlington |
PublicationTitle | Vaccine |
PublicationTitleAlternate | Vaccine |
PublicationYear | 2016 |
Publisher | Elsevier Ltd Elsevier Limited |
Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
References | Opio, Muyonga, Mulumba (bib0145) 2013; 8 McCormack, Ramjee, Kamali, Rees, Crook, Gafos (bib0180) 2010; 376 Janosky (bib0215) 2002; 288 Vandepitte, Bukenya, Weiss, Nakubulwa, Francis, Hughes (bib0165) 2011; 38 Ruzagira, Wandiembe, Abaasa, Levin, Bwanika, Bahemuka (bib0225) 2011; 6 (bib0120) 2010 Seeley, Nakiyingi-Miiro, Kamali, Mpendo, Asiki, Abaasa (bib0170) 2012; 39 Halpern, Karlawish, Berlin (bib0210) 2002; 288 Asiki, Abaasa, Ruzagira, Kibengo, Bahemuka, Mulondo (bib0135) 2013; 31 Van Damme, Govinden, Mirembe, Guédou, Solomon, Becker (bib0185) 2008; 359 Ondondo, Waithera Ng’ang’a, Mpoke, Kiptoo, Bukusi (bib0150) 2014; 4 Kamali, Price, Lakhi, Karita, Inambao, Sanders (bib0125) 2015; 10 Kiwanuka, Mpendo, Nalutaaya, Wambuzi, Nanvubya, Kitandwe (bib0130) 2014; 14 Peterson, Nanda, Opoku, Ampofo, Owusu-Amoako, Boakye (bib0195) 2007; 2 Abaasa, Asiki, Mpendo, Levin, Seeley, Nielsen (bib0230) 2015; 8 Baeten, Donnell, Ndase, Mugo, Campbell, Wangisi (bib0200) 2012; 367 Smith, Tapsoba, Peshu, Sanders, Jaffe (bib0155) 2009; 374 Feldblum, Adeiga, Bakare, Wevill, Lendvay, Obadaki (bib0190) 2008; 3 Asiki, Mpendo, Abaasa, Agaba, Nanvubya, Nielsen (bib0160) 2011; 87 Schroder, Carey, Vanable (bib0220) 2003; 26 McCoy, Padian, Balkus (bib0205) 2010 Ruzagira, Wandiembe, Bufumbo, Levin, Price, Grosskurth (bib0140) 2009; 14 Nunn, McCormack, Crook, Pool, Rutterford, Hayes (bib0175) 2009; 10 14534028 - Ann Behav Med. 2003 Oct;26(2):104-23 18669425 - N Engl J Med. 2008 Jul 31;359(5):463-72 12413365 - JAMA. 2002 Nov 6;288(17):2118; author reply 2119 12117401 - JAMA. 2002 Jul 17;288(3):358-62 24021306 - Vaccine. 2013 Oct 17;31(44):5055-61 19207177 - Trop Med Int Health. 2009 Feb;14 (2):196-203 20179575 - AIDS. 2010 Mar 13;24(5):621-35 21835763 - Sex Transm Infect. 2011 Oct;87(6):511-5 25242015 - BMC Public Health. 2014 Sep 22;14:986 18091987 - PLoS One. 2007 Dec 19;2(12):e1312 22784037 - N Engl J Med. 2012 Aug 2;367(5):399-410 19860888 - Trials. 2009 Oct 27;10:99 22592828 - Sex Transm Dis. 2012 Jun;39(6):433-9 21677779 - PLoS One. 2011;6(6):e20684 26703879 - BMC Res Notes. 2015 Dec 24;8:815 18213382 - PLoS One. 2008 Jan 23;3(1):e1474 20851460 - Lancet. 2010 Oct 16;376(9749):1329-37 25602351 - PLoS One. 2015 Jan 20;10(1):e0116100 23330152 - Sex Transm Dis. 2011 Apr;38(4):316-23 23940638 - PLoS One. 2013 Aug 05;8(8):e70770 19616840 - Lancet. 2009 Aug 1;374(9687):416-22 Asiki (10.1016/j.vaccine.2016.02.048_bib0160) 2011; 87 McCoy (10.1016/j.vaccine.2016.02.048_bib0205) 2010 Kiwanuka (10.1016/j.vaccine.2016.02.048_bib0130) 2014; 14 Ruzagira (10.1016/j.vaccine.2016.02.048_bib0225) 2011; 6 Kamali (10.1016/j.vaccine.2016.02.048_bib0125) 2015; 10 Smith (10.1016/j.vaccine.2016.02.048_bib0155) 2009; 374 Seeley (10.1016/j.vaccine.2016.02.048_bib0170) 2012; 39 Ondondo (10.1016/j.vaccine.2016.02.048_bib0150) 2014; 4 McCormack (10.1016/j.vaccine.2016.02.048_bib0180) 2010; 376 Peterson (10.1016/j.vaccine.2016.02.048_bib0195) 2007; 2 Baeten (10.1016/j.vaccine.2016.02.048_bib0200) 2012; 367 Ruzagira (10.1016/j.vaccine.2016.02.048_bib0140) 2009; 14 Vandepitte (10.1016/j.vaccine.2016.02.048_bib0165) 2011; 38 Feldblum (10.1016/j.vaccine.2016.02.048_bib0190) 2008; 3 Halpern (10.1016/j.vaccine.2016.02.048_bib0210) 2002; 288 Abaasa (10.1016/j.vaccine.2016.02.048_bib0230) 2015; 8 (10.1016/j.vaccine.2016.02.048_bib0120) 2010 Asiki (10.1016/j.vaccine.2016.02.048_bib0135) 2013; 31 Opio (10.1016/j.vaccine.2016.02.048_bib0145) 2013; 8 Van Damme (10.1016/j.vaccine.2016.02.048_bib0185) 2008; 359 Janosky (10.1016/j.vaccine.2016.02.048_bib0215) 2002; 288 Schroder (10.1016/j.vaccine.2016.02.048_bib0220) 2003; 26 Nunn (10.1016/j.vaccine.2016.02.048_bib0175) 2009; 10 |
References_xml | – volume: 38 start-page: 316 year: 2011 ident: bib0165 article-title: HIV and other sexually transmitted infections in a cohort of women involved in high risk sexual behaviour in Kampala, Uganda publication-title: Sex Transm Dis contributor: fullname: Hughes – volume: 374 start-page: 416 year: 2009 end-page: 422 ident: bib0155 article-title: Men who have sex with men and HIV/AIDS in sub-Saharan Africa publication-title: Lancet contributor: fullname: Jaffe – volume: 39 start-page: 433 year: 2012 end-page: 439 ident: bib0170 article-title: High HIV incidence and socio-behavioral risk patterns in fishing communities on the shores of Lake Victoria, Uganda publication-title: Sex Transm Dis contributor: fullname: Abaasa – volume: 14 start-page: 986 year: 2014 ident: bib0130 article-title: An assessment of fishing communities around Lake Victoria, Uganda, as potential populations for future HIV vaccine efficacy studies: an observational cohort study publication-title: BMC Public Health contributor: fullname: Kitandwe – volume: 367 start-page: 399 year: 2012 end-page: 410 ident: bib0200 article-title: Antiretroviral prophylaxis for HIV prevention in heterosexual men and women publication-title: N Engl J Med contributor: fullname: Wangisi – volume: 14 start-page: 196 year: 2009 end-page: 203 ident: bib0140 article-title: Willingness to participate in preventive HIV vaccine trials in a community-based cohort in south western Uganda publication-title: Trop Med Int Health contributor: fullname: Grosskurth – volume: 2 start-page: e1312 year: 2007 ident: bib0195 article-title: SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana publication-title: PLoS One contributor: fullname: Boakye – volume: 288 start-page: 2118 year: 2002 end-page: 2119 ident: bib0215 article-title: The ethics of underpowered clinical trials publication-title: JAMA contributor: fullname: Janosky – volume: 31 start-page: 5055 year: 2013 end-page: 5061 ident: bib0135 article-title: Willingness to participate in HIV vaccine efficacy trials among high risk men and women from fishing communities along Lake Victoria in Uganda publication-title: Vaccine contributor: fullname: Mulondo – volume: 8 year: 2013 ident: bib0145 article-title: HIV infection in fishing communities of Lake Victoria Basin of Uganda—a Cross-Sectional Sero-Behavioral Survey publication-title: PLOS ONE contributor: fullname: Mulumba – volume: 8 start-page: 815 year: 2015 ident: bib0230 article-title: Factors associated with dropout in a long term observational cohort of fishing communities around lake Victoria, Uganda publication-title: BMC Res Notes contributor: fullname: Nielsen – volume: 10 start-page: 99 year: 2009 ident: bib0175 article-title: Microbicides Development Programme: design of a phase III trial to measure the efficacy of the vaginal microbicide PRO 2000/5 for HIV prevention publication-title: Trials contributor: fullname: Hayes – volume: 4 start-page: 219 year: 2014 ident: bib0150 article-title: Prevalence and incidence of HIV infection among Fishermen along Lake Victoria Beaches in Kisumu County, Kenya publication-title: World J AIDS contributor: fullname: Bukusi – volume: 3 start-page: 0001474 year: 2008 ident: bib0190 article-title: SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria publication-title: PLoS One contributor: fullname: Obadaki – volume: 359 start-page: 463 year: 2008 end-page: 472 ident: bib0185 article-title: Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission publication-title: N Engl J Med contributor: fullname: Becker – volume: 6 start-page: e20684 year: 2011 ident: bib0225 article-title: Prevalence and incidence of HIV in a rural community-based HIV vaccine preparedness cohort in Masaka, Uganda publication-title: PLoS One contributor: fullname: Bahemuka – year: 2010 ident: bib0120 article-title: Development ICoAa: Understanding the research process for new HIV prevention technologies – volume: 376 start-page: 1329 year: 2010 end-page: 1337 ident: bib0180 article-title: PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial publication-title: Lancet contributor: fullname: Gafos – volume: 87 start-page: 511 year: 2011 end-page: 515 ident: bib0160 article-title: HIV and syphilis prevalence and associated risk factors among fishing communities of Lake Victoria, Uganda publication-title: Sex Transm Infect contributor: fullname: Nielsen – year: 2010 ident: bib0205 article-title: Weighing the gold in the gold standard: challenges in HIV prevention research contributor: fullname: Balkus – volume: 10 start-page: e0116100 year: 2015 ident: bib0125 article-title: Creating an African HIV Clinical Research and Prevention Trials Network: HIV prevalence, incidence and transmission publication-title: PLOS ONE contributor: fullname: Sanders – volume: 288 start-page: 358 year: 2002 end-page: 362 ident: bib0210 article-title: The continuing unethical conduct of underpowered clinical trials publication-title: JAMA contributor: fullname: Berlin – volume: 26 start-page: 104 year: 2003 end-page: 123 ident: bib0220 article-title: Methodological challenges in research on sexual risk behavior: II. Accuracy of self-reports publication-title: Ann Behav Med: Publ Soc Behav Med contributor: fullname: Vanable – volume: 4 start-page: 219 issue: 02 year: 2014 ident: 10.1016/j.vaccine.2016.02.048_bib0150 article-title: Prevalence and incidence of HIV infection among Fishermen along Lake Victoria Beaches in Kisumu County, Kenya publication-title: World J AIDS doi: 10.4236/wja.2014.42027 contributor: fullname: Ondondo – volume: 374 start-page: 416 issue: 9687 year: 2009 ident: 10.1016/j.vaccine.2016.02.048_bib0155 article-title: Men who have sex with men and HIV/AIDS in sub-Saharan Africa publication-title: Lancet doi: 10.1016/S0140-6736(09)61118-1 contributor: fullname: Smith – volume: 87 start-page: 511 issue: 6 year: 2011 ident: 10.1016/j.vaccine.2016.02.048_bib0160 article-title: HIV and syphilis prevalence and associated risk factors among fishing communities of Lake Victoria, Uganda publication-title: Sex Transm Infect doi: 10.1136/sti.2010.046805 contributor: fullname: Asiki – volume: 288 start-page: 2118 issue: 17 year: 2002 ident: 10.1016/j.vaccine.2016.02.048_bib0215 article-title: The ethics of underpowered clinical trials publication-title: JAMA contributor: fullname: Janosky – year: 2010 ident: 10.1016/j.vaccine.2016.02.048_bib0120 – volume: 14 start-page: 986 issue: 1 year: 2014 ident: 10.1016/j.vaccine.2016.02.048_bib0130 article-title: An assessment of fishing communities around Lake Victoria, Uganda, as potential populations for future HIV vaccine efficacy studies: an observational cohort study publication-title: BMC Public Health doi: 10.1186/1471-2458-14-986 contributor: fullname: Kiwanuka – volume: 2 start-page: e1312 issue: 12 year: 2007 ident: 10.1016/j.vaccine.2016.02.048_bib0195 article-title: SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana publication-title: PLoS One doi: 10.1371/journal.pone.0001312 contributor: fullname: Peterson – volume: 3 start-page: 0001474 issue: 1 year: 2008 ident: 10.1016/j.vaccine.2016.02.048_bib0190 article-title: SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria publication-title: PLoS One doi: 10.1371/journal.pone.0001474 contributor: fullname: Feldblum – volume: 26 start-page: 104 issue: 2 year: 2003 ident: 10.1016/j.vaccine.2016.02.048_bib0220 article-title: Methodological challenges in research on sexual risk behavior: II. Accuracy of self-reports publication-title: Ann Behav Med: Publ Soc Behav Med doi: 10.1207/S15324796ABM2602_03 contributor: fullname: Schroder – volume: 31 start-page: 5055 issue: 44 year: 2013 ident: 10.1016/j.vaccine.2016.02.048_bib0135 article-title: Willingness to participate in HIV vaccine efficacy trials among high risk men and women from fishing communities along Lake Victoria in Uganda publication-title: Vaccine doi: 10.1016/j.vaccine.2013.08.080 contributor: fullname: Asiki – volume: 288 start-page: 358 issue: 3 year: 2002 ident: 10.1016/j.vaccine.2016.02.048_bib0210 article-title: The continuing unethical conduct of underpowered clinical trials publication-title: JAMA doi: 10.1001/jama.288.3.358 contributor: fullname: Halpern – volume: 376 start-page: 1329 issue: 9749 year: 2010 ident: 10.1016/j.vaccine.2016.02.048_bib0180 article-title: PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial publication-title: Lancet doi: 10.1016/S0140-6736(10)61086-0 contributor: fullname: McCormack – volume: 8 issue: 8 year: 2013 ident: 10.1016/j.vaccine.2016.02.048_bib0145 article-title: HIV infection in fishing communities of Lake Victoria Basin of Uganda—a Cross-Sectional Sero-Behavioral Survey publication-title: PLOS ONE doi: 10.1371/journal.pone.0070770 contributor: fullname: Opio – volume: 10 start-page: 99 issue: 1 year: 2009 ident: 10.1016/j.vaccine.2016.02.048_bib0175 article-title: Microbicides Development Programme: design of a phase III trial to measure the efficacy of the vaginal microbicide PRO 2000/5 for HIV prevention publication-title: Trials doi: 10.1186/1745-6215-10-99 contributor: fullname: Nunn – volume: 14 start-page: 196 issue: 2 year: 2009 ident: 10.1016/j.vaccine.2016.02.048_bib0140 article-title: Willingness to participate in preventive HIV vaccine trials in a community-based cohort in south western Uganda publication-title: Trop Med Int Health doi: 10.1111/j.1365-3156.2008.02200.x contributor: fullname: Ruzagira – volume: 367 start-page: 399 issue: 5 year: 2012 ident: 10.1016/j.vaccine.2016.02.048_bib0200 article-title: Antiretroviral prophylaxis for HIV prevention in heterosexual men and women publication-title: N Engl J Med doi: 10.1056/NEJMoa1108524 contributor: fullname: Baeten – year: 2010 ident: 10.1016/j.vaccine.2016.02.048_bib0205 contributor: fullname: McCoy – volume: 10 start-page: e0116100 issue: 1 year: 2015 ident: 10.1016/j.vaccine.2016.02.048_bib0125 article-title: Creating an African HIV Clinical Research and Prevention Trials Network: HIV prevalence, incidence and transmission publication-title: PLOS ONE doi: 10.1371/journal.pone.0116100 contributor: fullname: Kamali – volume: 39 start-page: 433 issue: 6 year: 2012 ident: 10.1016/j.vaccine.2016.02.048_bib0170 article-title: High HIV incidence and socio-behavioral risk patterns in fishing communities on the shores of Lake Victoria, Uganda publication-title: Sex Transm Dis doi: 10.1097/OLQ.0b013e318251555d contributor: fullname: Seeley – volume: 359 start-page: 463 issue: 5 year: 2008 ident: 10.1016/j.vaccine.2016.02.048_bib0185 article-title: Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission publication-title: N Engl J Med doi: 10.1056/NEJMoa0707957 contributor: fullname: Van Damme – volume: 38 start-page: 316 issue: 4 year: 2011 ident: 10.1016/j.vaccine.2016.02.048_bib0165 article-title: HIV and other sexually transmitted infections in a cohort of women involved in high risk sexual behaviour in Kampala, Uganda publication-title: Sex Transm Dis doi: 10.1097/OLQ.0b013e3182099545 contributor: fullname: Vandepitte – volume: 6 start-page: e20684 issue: 6 year: 2011 ident: 10.1016/j.vaccine.2016.02.048_bib0225 article-title: Prevalence and incidence of HIV in a rural community-based HIV vaccine preparedness cohort in Masaka, Uganda publication-title: PLoS One doi: 10.1371/journal.pone.0020684 contributor: fullname: Ruzagira – volume: 8 start-page: 815 issue: 1 year: 2015 ident: 10.1016/j.vaccine.2016.02.048_bib0230 article-title: Factors associated with dropout in a long term observational cohort of fishing communities around lake Victoria, Uganda publication-title: BMC Res Notes doi: 10.1186/s13104-015-1804-6 contributor: fullname: Abaasa |
SSID | ssj0005319 |
Score | 2.3713768 |
Snippet | Abstract Background Clinical trial participants may differ from the source population due to the demands of trial participation and self-selection, inadvertent... Clinical trial participants may differ from the source population due to the demands of trial participation and self-selection, inadvertent selection of a... Background Clinical trial participants may differ from the source population due to the demands of trial participation and self-selection, inadvertent... BACKGROUNDClinical trial participants may differ from the source population due to the demands of trial participation and self-selection, inadvertent selection... |
SourceID | pubmedcentral proquest crossref pubmed elsevier |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 1778 |
SubjectTerms | Acquired immune deficiency syndrome Adolescent Adult AIDS Alcohol Allergy and Immunology Condoms Demographics Estimate Estimates Feasibility studies Female Fish populations Fishing Fishing communities Health risks Hepatitis B virus HIV HIV Infections - epidemiology Human immunodeficiency virus Humans Implications Incidence Lentivirus Male Middle Aged Observational studies Patient Selection Prospective Studies Public health Retention Retroviridae Risk Assessment Risk taking Sample Sample Size Sexually transmitted diseases Size STD Syphilis Uganda - epidemiology Vaccines Volunteers Young Adult |
SummonAdditionalLinks | – databaseName: ProQuest Public Health Database dbid: 8C1 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3bbtQwELWgCISEEIRLFwoaJNSnps3F2di8ILSi2iIVVaJb7Ztlx05pH7LbZotU_ol_ZMa5bQGVx03szW1sj2fOnMPYe22NLY0VYSZTHfKxNaHIHA-d0aKwmS5yQ3HIw6_j6Yx_mWfzNuBWt7DKbk70E7VdFBQj34vznLjLkyj7uLwISTWKsquthMZddi-mhY4qxSdrEI_UC3vgNoOHPI7mQwXP3vnuD11Q6prQXWNP20kSQP9em_72Pf-EUK6tSftP2OPWmYRPzdd_yu64KmD3G3nJ64A9OGwT5wHbPmooqq934HiouKp3YBuOBvJq7POoieNBU54UsOCE8DK-aBe6v3vGfk16-UJYlDA9OAGK2Xt9UiDeDvSDncVj0FVegpcHAV1ZWJg-EoxHSKH3cgW18wDsmvpoIBJlINQ7lE2MDJa90Bi1mJ1SAOQDHKzh4QHdb6g1sR1DffZzuI_6OZvtfz6eTMNW-CEsMpGuwsw5UeI-05CzoYWMnJSlITyd1WlUoHVxI5NcWDPWseO2TBPJidexcCJP8OcLtlEtKrfJoOSZMDbmWVqmnMSzpI1tXHCZlNJl0o3YbvfJ1bLh91Ad8O1ctTaiyEZUlCi0kRHLO8NQ3SvE6dbV7divVaxqbKm-Rd7XjOYxpT4TmYyY6Hu27k3jtihcvf530a3OBNVwnX5EjNi7_jTODpTy0ZVbXPk2lAgViby1De5hcWbHy7xsrLp_FckYNwDoY-NT37D3vgGxk988U5199yzluJXGxUG-uv3WX7OH9JweC8W32Mbq8sq9QTdvZd76sfwbQwxXfQ priority: 102 providerName: ProQuest |
Title | Comparison of HIV incidence estimated in clinical trial and observational cohort settings in a high risk fishing population in Uganda: Implications for sample size estimates |
URI | https://www.clinicalkey.es/playcontent/1-s2.0-S0264410X16002292 https://dx.doi.org/10.1016/j.vaccine.2016.02.048 https://www.ncbi.nlm.nih.gov/pubmed/26923456 https://www.proquest.com/docview/1776150205 https://search.proquest.com/docview/1775169829 https://search.proquest.com/docview/1776668328 https://pubmed.ncbi.nlm.nih.gov/PMC4994889 |
Volume | 34 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfGJhAvCMpXYaBDQnta2nzH5m1Um1rQqgrWqW-WHTvQPaTV0iGNB_4j_kfu8rkyBBIvSePcyYl7uTv7zr9j7K0y2mTacCcSgXLC2GiHRzZ0rFY8NZFKE03rkKfTeDwPPyyixQ4bNXthKK2y1v2VTi-1dd0yrEdzuF4uh5_d0pa7C49CS75APbyH5ohitXtHk4_jaZfpEZT1PYjeIYZuI8_wYvBNpRTBpiSvuETvpEpAfzZRt13Q3zMpb5imk4fsQe1TwlH12I_Yjs177G5VZfK6x-6d1vHzHjuYVUjV14dw1m28Kg7hAGYdhjXy9M4pTabcqwsN-2P2c9RWLYRVBuPJOdBSfVmWFAiuA91fa7ANmg2XUFYFAZUbWOl2ARhbqDDv5QYKW-ZdF8SjgLCTgZLdIauWxmDd1hcjivkXWvd4B5MbafCAXjcUikCOoVh-756jeMLmJ8dno7FT13tw0ogHGyeylmc4vdTkYyguXCtEpimNzqjATVGoQi38hBsdK8-GJgt8ERKcY2p54uPlU7abr3L7nEEWRlwbL4yCLAipZpYwnvHSUPiZsJGwfTZo_mK5rmA9ZJPvdiFrmZAkE9L1JcpEnyWNIMhmCFHL2qL-5AvpyQIp5S2x7DPecm5JtkSj9a9O9xuRk10_SUIg_r4b9dmb9jYqBYr0qNyurkoain9yX_yVBqeuqNCxm2eVFLdD4cfo96NrjW-9Jd8tAYGSb9_Jl19LcHKcQaNNEC_-_61fsvt0VaZHhftsd3N5ZV-h57fRr9mdwQ8Pj8kiwSMf4e_qW8fz--Pp7NMv1IdilA |
link.rule.ids | 230,314,780,784,885,4502,12056,12223,21388,24116,27924,27925,31719,31720,33266,33267,33744,33745,43310,43579,43805,45585,45679,73745,74014,74302 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1bb9MwFLagExcJISgDCgMOEtrTsuXiNDEvCKZNLaxVBe3UN8uOHdgekrJ0SOM_8R85J9cN0HhMYse5HNvH53z-PsbeKKNNqk3shCJQDh8a7cSh5Y7VKk5MqJJIUxxyMh2OFvzjMlzWAbeihlU2Y2I5UJs8oRj5nhdFxF3uu-G71XeHVKMou1pLaNxkG8ScHvbYxoeD6exzB_IISmkPXGhwh3vustvDs3e6-0MllLwmfNewJO4kEaB_z05_e59_gigvzUqHD9j92p2E99X_f8hu2KzPblUCkxd9dntSp877bHtWkVRf7MC823NV7MA2zDr6aqxzr4rkQbVBqc_6x4SYKbftQnO7R-zXfitgCHkKo_ExUNS-VCgFYu5AT9gaPAfN3ksoBUJAZQZy3caC8Qxp9J6tobAlBLugOgqIRhkI9w5pFSWDVSs1RiUWXykE8hbGlxDxgA44FIr4jqE4-dk9R7HJFocH8_2RU0s_OEkYB2sntDZOcaWpyd1QsXCtEKkmRJ1RgZugfXEt_Cg2eqg8y00a-IITs2Ni48jHw8esl-WZfcog5WGsjcfDIA04yWcJ4xkv4cJPhQ2FHbDd5pfLVcXwIRvo26msbUSSjUjXl2gjAxY1hiGbT4gDri3q3l9ITxZYUn5xS2_TXXqU_PSFP2BxW7N2cCrHReL89b9GtxoTlF07bZ8YsNftZRwfKOmjMpufl2UoFRr74toyuIrFsR2beVJZdfsp_CEuAdDLxre-Yu9tAeInv3olO_lW8pTjYhqnB_Hs-kd_xe6M5pMjeTSefnrO7tI7l8govsV667Nz-wKdvrV-Wffs38CzXAs |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1bb9MwFLagExMSQlAYFAYcJLSnZc3FaWJeEIxVLbCqgnXqm2XHDmwPSVk6pPGf-I-ck-sGaDw2sZvb8fHxOZ-_j7FXymiTahM7oQiUw0dGO3FouWO1ihMTqiTSlIc8nI0mC_5hGS5r_FNRwyobn1g6apMnlCMfelFE3OW-Gw7TGhYxfz9-s_rukIIUVVprOY2bbANnRdfvsY13B7P55w7wEZQyH7jo4A733GW3n2d4uvdDJVTIJqzXqCTxJEGgf89Uf0eifwIqL81Q43vsbh1awtvKFu6zGzbrs1uV2ORFn20e1mX0PtuZV4TVF7tw1O2_KnZhB-YdlTX2uVNl9aDarNRn_WNCz5RbeKH5uwfs134rZgh5CpPpMVAGv1QrBWLxwKjYGjwGzT5MKMVCQGUGct3mhfEI6fWeraGwJRy7oD4KiFIZCAMPaZUxg1UrO0YtFl8pHfIappfQ8YDBOBSKuI-hOPnZ3UfxkC3GB0f7E6eWgXCSMA7WTmhtnOKqU1PooWLhWiFSTeg6owI3QVvjWvhRbPRIeZabNPAFJ5bHxMaRjz-3WC_LM_uYQcrDWBuPh0EacJLSEsYzXsKFnwobCjtge80nl6uK7UM2MLhTWduIJBuRri_RRgYsagxDNq8Qna8tak9QSE8W2FJ-ccvI0116VAj1hT9gcduzDnaqIEbiXPa_i243Jii767TjY8BetqfRV1ABSGU2Py_bUFk09sW1bXBFi34eL_Oosur2VfgjXA5gxI1PfcXe2wbEVX71THbyreQsx4U1ThXiyfW3_oJt4qCWn6azj0_ZbXrkEiTFt1lvfXZun2H8t9bP64H9G-q9YDg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparison+of+HIV+incidence+estimated+in+clinical+trial+and+observational+cohort+settings+in+a+high+risk+fishing+population+in+Uganda%3A+Implications+for+sample+size+estimates&rft.jtitle=Vaccine&rft.au=Abaasa%2C+Andrew&rft.au=Asiki%2C+Gershim&rft.au=Price%2C+Matthew+A.&rft.au=Ruzagira%2C+Eugene&rft.date=2016-04-04&rft.issn=0264-410X&rft.volume=34&rft.issue=15&rft.spage=1778&rft.epage=1785&rft_id=info:doi/10.1016%2Fj.vaccine.2016.02.048&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_vaccine_2016_02_048 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F0264410X%2FS0264410X16X00151%2Fcov150h.gif |